金陵药业
(000919)
| 流通市值：40.32亿 | | | 总市值：42.60亿 |
| 流通股本：5.90亿 | | | 总股本：6.24亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,323,186,708.62 | 1,770,945,293.91 | 1,254,484,540.88 | 1,355,659,403.85 |
| 结算备付金 | 0 | 0 | - | - |
| 拆出资金 | 0 | 0 | - | - |
| 衍生金融资产 | 0 | 0 | - | - |
| 应收票据及应收账款 | 767,314,781.13 | 686,725,108.33 | 747,662,546.04 | 648,310,164.91 |
| 其中：应收票据 | 196,772,224.74 | 247,800,384.48 | 207,040,765.34 | 167,096,871.81 |
| 应收账款 | 570,542,556.39 | 438,924,723.85 | 540,621,780.7 | 481,213,293.1 |
| 应收款项融资 | 0 | 0 | - | - |
| 预付款项 | 11,516,742.83 | 4,490,272.62 | 19,861,369.15 | 12,827,591.63 |
| 应收保费 | 0 | 0 | - | - |
| 应收分保账款 | 0 | 0 | - | - |
| 应收分保合同准备金 | 0 | 0 | - | - |
| 其他应收款合计 | 7,910,505.91 | 7,231,221.12 | 9,031,224.78 | 9,391,271.72 |
| 其中:应收利息 | 0 | 0 | - | - |
| 应收股利 | 0 | 0 | - | - |
| 买入返售金融资产 | 0 | 0 | - | - |
| 存货 | 250,837,970.04 | 271,624,277.17 | 248,069,135.45 | 244,205,920.06 |
| 合同资产 | 0 | 0 | - | - |
| 一年内到期的非流动资产 | 236,024,657.53 | 165,219,589.04 | 10,000,000 | 10,000,000 |
| 其他流动资产 | 12,754,169.71 | 5,811,480.62 | 8,702,843.33 | 7,802,723.63 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,651,601,393.66 | 3,618,093,743.35 | 3,149,840,677.79 | 3,083,477,655.37 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | 0 | 0 | - | - |
| 债权投资 | 0 | 0 | - | - |
| 其他债权投资 | 0 | 0 | - | - |
| 长期应收款 | 0 | 0 | - | - |
| 长期股权投资 | 58,637,694.18 | 60,309,482.72 | 253,729,611.24 | 249,637,763.39 |
| 其他权益工具投资 | 406,542.26 | 586,084.34 | 1,013,253.08 | 1,013,253.08 |
| 其他非流动金融资产 | 0 | 0 | - | - |
| 投资性房地产 | 8,281,688.01 | 8,532,982.86 | 7,681,145.21 | 7,919,474.69 |
| 固定资产 | 1,376,306,537.72 | 1,396,190,053.42 | 1,279,445,063.91 | 1,298,800,055.66 |
| 在建工程 | 96,510,751.29 | 71,782,383.5 | 28,010,980.92 | 25,583,445.71 |
| 生产性生物资产 | 1,068,469.02 | 1,119,616.42 | 1,172,255.12 | 1,228,107.74 |
| 油气资产 | 0 | 0 | - | - |
| 使用权资产 | 31,611,339.55 | 32,213,882.75 | 3,915,143.75 | 4,362,882.9 |
| 无形资产 | 321,941,347.67 | 325,673,286.79 | 255,797,658.14 | 259,971,038.09 |
| 开发支出 | 0 | 0 | 3,498,113.21 | - |
| 商誉 | 62,418,871.63 | 62,418,871.63 | 27,331,541.79 | 27,331,541.79 |
| 长期待摊费用 | 87,462,249.35 | 83,339,882.94 | 11,401,344.56 | 10,567,739.66 |
| 递延所得税资产 | 15,834,764.38 | 12,493,908.75 | - | 8,291,470.07 |
| 其他非流动资产 | 346,287,001.27 | 416,100,846.12 | 333,012,502.87 | 324,039,023.23 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,406,767,256.33 | 2,470,761,282.24 | 2,206,008,613.8 | 2,218,745,796.01 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 6,058,368,649.99 | 6,088,855,025.59 | 5,355,849,291.59 | 5,302,223,451.38 |
| 流动负债: | | | | |
| 短期借款 | 0 | 0 | - | - |
| 向中央银行借款 | 0 | 0 | - | - |
| 吸收存款及同业存放 | 0 | 0 | - | - |
| 拆入资金 | 0 | 0 | - | - |
| 交易性金融负债 | 0 | 0 | - | - |
| 衍生金融负债 | 0 | 0 | - | - |
| 应付票据及应付账款 | 597,771,165.43 | 595,307,084.31 | 511,607,662.63 | 488,827,053.45 |
| 其中：应付票据 | 47,424,300.21 | 37,889,967.14 | 47,159,118.42 | 44,816,133.11 |
| 应付账款 | 550,346,865.22 | 557,417,117.17 | 464,448,544.21 | 444,010,920.34 |
| 预收款项 | 535,753.08 | 1,260,079.35 | 1,259,270.5 | 1,918,089.4 |
| 合同负债 | 21,915,926.77 | 35,600,964.59 | 24,424,601.82 | 21,558,763.23 |
| 卖出回购金融资产款 | 0 | 0 | - | - |
| 应付手续费及佣金 | 0 | 0 | - | - |
| 应付职工薪酬 | 57,137,192.39 | 117,181,894.15 | 88,115,710.83 | 89,177,011.75 |
| 应交税费 | 56,456,415.49 | 45,274,782.9 | 38,213,193.99 | 44,877,521.44 |
| 其他应付款合计 | 228,766,199.47 | 227,444,183.35 | 228,792,461.91 | 205,130,989.61 |
| 其中:应付利息 | 0 | 0 | - | - |
| 应付股利 | 0 | 0 | - | - |
| 应付分保账款 | 0 | 0 | - | - |
| 保险合同准备金 | 0 | 0 | - | - |
| 代理买卖证券款 | 0 | 0 | - | - |
| 代理承销证券款 | 0 | 0 | - | - |
| 一年内到期的非流动负债 | 2,765,780.11 | 4,233,069.2 | 2,306,469.24 | 2,614,744.62 |
| 其他流动负债 | 742,733.93 | 724,381.91 | 1,891,613.55 | 1,151,563.41 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 966,091,166.67 | 1,027,026,439.76 | 896,610,984.47 | 855,255,736.91 |
| 非流动负债: | | | | |
| 长期借款 | 150,123,750 | 150,123,750 | - | - |
| 应付债券 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 租赁负债 | 36,697,789.91 | 34,851,069.72 | 1,515,966.56 | 1,870,066.72 |
| 长期应付款 | 0 | 0 | - | - |
| 长期应付职工薪酬 | 0 | 0 | - | - |
| 预计负债 | 0 | 0 | - | - |
| 递延收益 | 961,554.54 | 1,001,416.56 | 387,807.27 | 387,807.27 |
| 递延所得税负债 | 30,825,100 | 27,275,725.9 | 19,831,751.91 | 22,994,218.1 |
| 其他非流动负债 | 0 | 0 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 218,608,194.45 | 213,251,962.18 | 21,735,525.74 | 25,252,092.09 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,184,699,361.12 | 1,240,278,401.94 | 918,346,510.21 | 880,507,829 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 623,708,628 | 623,708,628 | 629,060,528 | 629,060,528 |
| 其他权益工具 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 资本公积 | 1,097,873,201.13 | 1,097,873,201.13 | 1,105,691,414.84 | 1,105,691,414.84 |
| 减:库存股 | 6,768,819 | 6,768,819 | 26,994,240 | 26,994,240 |
| 其他综合收益 | 2,512,226.61 | 2,512,226.61 | 2,551,457.02 | 2,512,226.61 |
| 专项储备 | 523,709.21 | 577,165.24 | 916,877.51 | 951,921.22 |
| 盈余公积 | 415,026,062.19 | 415,026,062.19 | 408,647,578.17 | 408,647,578.17 |
| 一般风险准备 | 0 | 0 | - | - |
| 未分配利润 | 1,681,144,362.39 | 1,658,162,373.25 | 1,674,591,243.63 | 1,655,041,385.6 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,814,019,370.53 | 3,791,090,837.42 | 3,794,464,859.17 | 3,774,910,814.44 |
| 少数股东权益 | 1,059,649,918.34 | 1,057,485,786.23 | 643,037,922.21 | 646,804,807.94 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,873,669,288.87 | 4,848,576,623.65 | 4,437,502,781.38 | 4,421,715,622.38 |
| 负债和股东权益合计 | 6,058,368,649.99 | 6,088,855,025.59 | 5,355,849,291.59 | 5,302,223,451.38 |
| 公告日期 | 2025-04-28 | 2025-03-29 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |